Study of the Incidence of SARS-CoV-2 Infection (COVID-19)
Condition(s) studied
Investigational drug(s) / intervention(s)
blood sampling: blood sampling at J0, M6, M12, M24, M36, M48, M60
Study summary
This is a prospective observational cohort study that will define the prevalence and incidence of CA-SARS-Cov2 infection using serological and PCR tests in a group of subjects during deconfinement. The team wishes to include approximately 1000 subjects in this study.
The health crisis through containment has also created unprecedented environmental conditions with the very clear decrease in economic activities and a consequent decrease in exposure to the main air pollutants. The aim is therefore to carry out a case-control study in which each subject will be his or her own control in unexposed condition (to PM2.5, PM10, NO...) then exposed (after the recovery of economic activity and the usual levels of air pollutants) and to measure the impact of these pollutants on the immune system and epigenetic markers taking into account seasonality.
The occurrence of infectious, cardiovascular, allergic and autoimmune events will then be measured according to the immunological profiles measured at inclusion.
Eligibility
Primary outcome measure(s)
- positive serologies — 12 months
number of positive serologies
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University Nice Hospital | Nice | France | Recruiting |
More Centre Hospitalier Universitaire de Nice trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04429594 on ClinicalTrials.gov ↗ ← All trials in France